Kanāda - angļu - Health Canada

takeda canada inc - lanthanum (lanthanum carbonate hydrate) - tablet (chewable) - 250mg - lanthanum (lanthanum carbonate hydrate) 250mg - phosphate-removing agents

Kanāda - angļu - Health Canada

takeda canada inc - lanthanum (lanthanum carbonate hydrate) - tablet (chewable) - 500mg - lanthanum (lanthanum carbonate hydrate) 500mg - phosphate-removing agents

Kanāda - angļu - Health Canada

takeda canada inc - lanthanum (lanthanum carbonate hydrate) - tablet (chewable) - 750mg - lanthanum (lanthanum carbonate hydrate) 750mg - phosphate-removing agents

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000 mg - chewable tablet - 1000 mg - active: lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000 mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 954mg equivalent to elemental lanthanum 500mg - chewable tablet - 500 mg - active: lanthanum carbonate hydrate 954mg equivalent to elemental lanthanum 500mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg - chewable tablet - 750 mg - active: lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000mg - powder for oral solution - 1000 mg - active: lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg - powder for oral solution - 750 mg - active: lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - lanthanum carbonate hydrate -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

shire australia pty ltd - lanthanum carbonate hydrate -